Get the Stockscreener App
0.3754
2.71%
0.0029
After Hours:
.39
0.0146
+3.89%
Generation Bio Co stock is traded at $0.3754, with a volume of 522.07K.
It is up +2.71% in the last 24 hours and down -28.15% over the past month.
See More
Previous Close:
$0.3725
Open:
$0.365
24h Volume:
522.07K
Relative Volume:
1.01
Market Cap:
$24.96M
Revenue:
-
Net Income/Loss:
$-126.61M
P/E Ratio:
-0.1915
EPS:
-1.96
Net Cash Flow:
$-60.14M
1W Performance:
-5.53%
1M Performance:
-28.15%
6M Performance:
-83.44%
1Y Performance:
-90.34%
1-Day Range:
$0.3462
$0.4017
1-Week Range:
$0.3462
$0.4332
52-Week Range:
$0.3462
$4.52
Generation Bio Co Stock (GBIO) Company Profile
Name
Generation Bio Co
Sector
Industry
Phone
857-529-5908
Address
301 BINNEY STREET, CAMBRIDGE
Compare GBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GBIO
Generation Bio Co
|
0.3754 | 24.96M | 0 | -126.61M | -60.14M | -1.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.56 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.78 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
550.00 | 32.85B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.95 | 28.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
220.54 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Generation Bio Co Stock (GBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-19-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Nov-08-22 | Initiated | Canaccord Genuity | Buy |
| Dec-14-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-08-21 | Initiated | JMP Securities | Mkt Outperform |
| Feb-24-21 | Initiated | William Blair | Outperform |
| Feb-18-21 | Initiated | Needham | Buy |
| Jul-07-20 | Initiated | Cowen | Outperform |
| Jul-07-20 | Initiated | JP Morgan | Overweight |
| Jul-07-20 | Initiated | Jefferies | Buy |
| Jul-07-20 | Initiated | Wedbush | Outperform |
View All
Generation Bio Co Stock (GBIO) Latest News
Layoff Tracker: Relay Will Cut 70 Employees, Affecting Research Budget by 75% - BioSpace
Generation Bio stock hits 52-week low at $0.4 amid steep decline - Investing.com Australia
Generation Bio to Present at the Needham 24th Annual Virtual Healthcare Conference - The Manila Times
Generation Bio Takes Center Stage: CEO Fireside Chat at Major Healthcare Conference - Stock Titan
Charles Schwab Investment Management Inc. Cuts Stake in Generation Bio Co. (NASDAQ:GBIO) - Defense World
Generation Bio Co. (GBIO) Reports Q4 Loss, Tops Revenue Estimates - MSN
Generation Bio stock hits 52-week low at $0.47 By Investing.com - Investing.com South Africa
Generation Bio stock hits 52-week low at $0.47 - Investing.com India
Generation Bio’s (GBIO) Buy Rating Reaffirmed at Canaccord Genuity Group - Defense World
Generation Bio’s SWOT analysis: stock pivots to T-cell focus amid market caution By Investing.com - Investing.com South Africa
Generation Bio’s SWOT analysis: stock pivots to T-cell focus amid market caution - Investing.com Australia
Generation Bio’s (GBIO) Outperform Rating Reiterated at Wedbush - Defense World
Generation Bio Co. (NASDAQ:GBIO) Not Doing Enough For Some Investors As Its Shares Slump 29% - Simply Wall St
Generation Bio Co. Advances in Autoimmune Therapeutics - TipRanks
Generation Bio Co reports results for the quarter ended December 31Earnings Summary - TradingView
Generation Bio stock holds Market Perform rating at JMP - Investing.com India
Generation Bio stock holds Market Perform rating at JMP By Investing.com - Investing.com UK
Generation Bio earnings missed by $0.02, revenue topped estimates - Investing.com South Africa
Generation Bio Co (GBIO) Q4 2024 Earnings: EPS Misses Estimate o - GuruFocus.com
Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Generation Bio Co. Advances T Cell-Selective siRNA Therapeutics for Autoimmune Diseases, Announces Robust Financial Position - Nasdaq
Generation Bio's Breakthrough: 98% T Cell Success Powers $185M Cash Runway Through 2027 - StockTitan
Generation Bio Co (GBIO)’s stock rises to 0.52 per share - US Post News
Generation Bio stock hits 52-week low at $0.52 By Investing.com - Investing.com Australia
A Guide To The Risks Of Investing In Generation Bio Co (GBIO) - Knox Daily
Generation Bio stock hits 52-week low at $0.52 - Investing.com
Generation Bio (GBIO) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Contrasting Generation Bio (NASDAQ:GBIO) & Anthera Pharmaceuticals (OTCMKTS:ANTH) - Defense World
Generation Bio faces Nasdaq delisting over share price By Investing.com - Investing.com Canada
Generation Bio faces Nasdaq delisting over share price - Investing.com India
Generation Bio to Present at the TD Cowen 45th Annual Health Care Conference - The Manila Times
Can Generation Bio's Autoimmune Disease Strategy Transform T Cell Treatment? CEO Reveals Plans - StockTitan
Kineticos Launches Kinvard Bio to Advance Next-Generation Antibiotics in the Fight Against Antimicrobial Resistance - PR Newswire
Generation Bio stock hits 52-week low at $0.6 amid sharp decline - Investing.com Nigeria
Generation Bio stock hits 52-week low at $0.6 amid sharp decline By Investing.com - Investing.com South Africa
Generation Bio Co Stock (GBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Generation Bio Co Stock (GBIO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Quinn Anthony G. | Director |
Jan 13 '25 |
Buy |
0.97 |
85,000 |
82,450 |
299,286 |
| Howze Yalonda | CHIEF LEGAL OFFICER |
Oct 15 '24 |
Option Exercise |
2.42 |
3,347 |
8,100 |
15,169 |
| Paone Antoinette | CHIEF OPERATING OFFICER |
Jul 01 '24 |
Sale |
2.74 |
6,719 |
18,410 |
13,807 |
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):